Comparative exposure data – 1st doses

Age group	Estimated number of first AZ doses in UK (1,000,000s)	%	Estimated number of first Pfizer doses in UK (1,000,000s)	%
18-29 yrs	■	■	■	■
30-39 yrs	■	■	■	■
40-49 yrs	■	■	■	■
50-64 yrs	■	■	■	■
65+ yrs	■	■	■	■
Total	19.7	100	10.9	100

(data lock 29th March)

Incidence rate – further analysis of CVST (all cases assumed to be after 1st dose)

Age group	Estimated number of first doses in UK (1,000,000s)	Total number of cases	Case incidence rate (per 1 million doses)	Exc. unlikely cases	Case incidence rate (per 1 million doses)	Number of fatal cases (inc. unlikely)	Fatal incidence rate (per 1 million doses)
18-29 yrs	■	10	■	9	■	5	■
30-39 yrs	■	7	■	7	■	3	■
40-49 yrs	■	4	■)	4	■	0	-
50-64 yrs	■	10	■	7	■	4	■
65+ yrs	■	3	■	3	■	2	■
Total*	19.7	39	2.0 (1.4,2.7)	35	1.8 (1.2,2.5)	15	0.8 (0.4,1.3)

* Includes 5 patients with unknown age (none unlikely, 1 fatal)

Incidence rate – further analysis of CVST (all cases assumed to be after 1st dose)

Age/sex group	Estimated number of first doses in UK (1,000,000s)	Total number of cases	Case incidence rate (per 1 million doses)	Total number of cases (exc. unlikely)	Case incidence rate (per 1 million doses)
Males <50	■	8	■	7	■
Males 50+	■	2	■	1	■
Total*	9.4	13	1.4 (0.7,2.4)	11	1.2 (0.6,2.1)

* Includes 3 males with unknown age

Age/sex group	Estimated number of first doses in UK (1,000,000s)	Total number of cases	Case incidence rate (per 1 million doses)	Total number of cases (exc. unlikely)	Case incidence rate (per 1 million doses)
Females <50	■	13	■	13	■
Females 50+	■	11	■	9	■
Total**	10.3	26	2.5 (1.7,3.7)	24	2.3 (1.5,3.5)

** Includes 2 females with unknown age

(data lock 29th March)

Incidence rate – further analysis (CVST + other TE, all cases assumed to be after 1st dose)

Age group	Estimated number of first doses in UK (1,000,000s)	Total number of cases	Case incidence rate (per 1 million doses)	Exc. unlikely cases	Case incidence rate (per 1 million doses)	Number of fatal cases (inc. unlikely)	Fatal incidence rate (per 1 million doses)
18-29 yrs	■	12	■	11	■)	5	■
30-39 yrs	■	13	■	13	■	5	■
40-49 yrs	■	6	■	6	■	0	-
50-64 yrs	■	17	■	13	■	5	■
65+ yrs	■	10	■	10	■	3	■
Total*	19.7	67	3.4 (2.6,4.3)	62	3.2 (2.4,4.0)	19	1.0 (0.6,1.5)

* Includes 9 patients with unknown age (non unlikely,1 fatal)

(data lock 29th March)

Benefit risk assessment

Estimates of vaccine effectiveness have been calculated by PHE.

Benefit risk assessment

- Cases and long COVID – ████████████████████████████████

Age group	Number of cases prevented per 1m vaccinations	Number of long COVID cases prevented per 1m vaccinations*
██████	██████	███
██████	██████	████
██████	██████	████
██████	██████	████
██████	██████	████
██████	██████	████
███	██████	████

* Assumes 10% of cases experience long COVID

Benefit risk assessment

- Hospitalisation and mortality (per 1 million doses)

	No. of hospitalisations prevented	No. of deaths (within 28 days) prevented*	No. of cases of CVST inc. unlikely (95% CI)	No. of cases of CVST exc. unlikely (95% CI)	No. of fatal cases of CVST inc. unlikely (95% CI)
▌		▌	██████	█████	█████
▌	▌	▌	██████	█████	█████
▌		▌	█████	█████	▏
▌		▌	█████	█████	████
▌	▌	▌			
▌	▌	▌	█████	█████	█████

* Assuming 2 doses given   (data lock 29th March)

Benefit risk assessment

- Hospitalisation and mortality (per 1 million doses)

Age group	No. of hospitalisations prevented	No. of deaths (within 28 days) prevented*	No. of cases of CVST+TE inc. unlikely (95% CI)	No. of cases of CVST+TE exc. unlikely (95% CI)	No. of fatal cases of CVST+TE inc. unlikely (95% CI)
███		▇	███████	██████	██████
███					
███	▇	▇	██████	█████	█████
███					
██		▇	█████	█████	▏
██					
███	▇	▇	█████	█████	█████
███					
███		▇			
███	████	▇	██████	██████	█████

* Assuming 2 doses given

(data lock 29th March)